NASDAQ
20.05.26 | 17:28
0,690 US-Dollar
-7,23 % -0,054
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:12 | Evogene misses Q1 estimates | 3 | Seeking Alpha | ||
| 13:00 | Evogene Reports First Quarter 2026 Financial Results | 525 | PR Newswire | Conference call and webcast: today, May 20, 2026, 9:00 AM ET
REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering... ► Artikel lesen | |
| Di | Evogene Q1 2026 Earnings Preview | 3 | Seeking Alpha | ||
| Mo | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.04. | Evogene receives Nasdaq delisting warning over share price | 1 | Investing.com | ||
| 02.04. | Evogene receives Nasdaq notification | 2 | Seeking Alpha | ||
| EVOGENE Aktie jetzt für 0€ handeln | |||||
| 02.04. | Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification | 118 | PR Newswire | REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry... ► Artikel lesen | |
| 26.03. | Evogene Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 26.03. | Evogene Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 05.03. | Evogene Earnings Review: Q4 Summary | 2 | Benzinga.com | ||
| 05.03. | Evogene GAAP EPS of -$0.61, revenue of $0.31M | 1 | Seeking Alpha | ||
| 05.03. | Evogene Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 05.03. | Evogene Reports Fourth Quarter and Full Year 2025 Financial Results | 711 | PR Newswire | Conference call and webcast: today, March 05, 2026, 9:00 AM ET
REHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering... ► Artikel lesen | |
| 04.03. | An Overview of Evogene's Earnings | 1 | Benzinga.com | ||
| 25.02. | Evogene refocuses on AI drug discovery platform ChemPass | 10 | Investing.com | ||
| 25.02. | Evogene Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.02. | Evogene Releases CEO Letter to Shareholders | 449 | PR Newswire | Updating on Strategic Progress and Outlook
REHOVOT, Israel, Feb. 25, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry... ► Artikel lesen | |
| 18.02. | Evogene and QUT partner on AI-based cancer therapies | 1 | Pharmaceutical Technology | ||
| 11.02. | Evogene Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.02. | Evogene sichert sich 3,4 Millionen US-Dollar durch Anreizvereinbarung für Optionsscheine | 3 | Investing.com Deutsch |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,15 | +3,24 % | Ihre wichtigsten Termine: Alle Blicke auf: Fraport, Biontech, Nagarro, Freenet & Intercontinental Exchange | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
| QIAGEN | 29,910 | +0,66 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 41,910 | +6,40 % | Roivant Sciences: Aktie schießt nach Gewinnwende und Moderna-Vergleich in die Höhe | ||
| STRYKER | 273,60 | +0,44 % | Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business | WASHINGTON (dpa-AFX) - Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price... ► Artikel lesen | |
| BIOGEN | 161,00 | -1,95 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 42,000 | +2,41 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 554,00 | +2,01 % | Regeneron Pharmaceuticals-Aktie -12%: Unterschätzen alle diesen Pharmakonzern? | Mit einem Kurssturz von -12% hält die Regeneron Pharmaceuticals-Aktie am Montagmorgen fest die rote Laterne im S&P 500-Index in der Hand. Warum bricht der Kurs des US-Pharmakonzerns zum Wochenbeginn... ► Artikel lesen | |
| VIVOSIM LABS | 1,290 | +1,57 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,126 | +6,63 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INFLARX | 2,182 | +5,72 % | Warum InflaRx NV heute im Fokus erfahrener Anleger steht: Hier baut sich gerade etwas Großes auf - Was ich meinen Lesern jetzt rate | ||
| INTELLIA THERAPEUTICS | 10,660 | +3,70 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| EDITAS MEDICINE | 2,190 | +2,82 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| BIOMARIN PHARMACEUTICAL | 43,030 | +0,26 % | BioMarin Pharmaceutical Inc.: BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency | ENERGY 3 study met 1 of 2 co-primary endpoints in children with ENPP1 deficiency
Treatment with BMN 401 led to statistically significant increases in plasma inorganic... ► Artikel lesen |
Das Unternehmen EVOGENE LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -7,23 % bei einem Aktienkurs von 0,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOGENE LTD finden Sie auf Wallstreet Online.